This is a story about an experimental new blood thinner for use by people who have atrial fibrillation. This story delivers a sound presentation of why this drug may have benefit over the commonly used warfarin.
The need for medication to reduce clotting risk from atrial fibrillation is common and there is long-standing interest in eliminating the need for routine monitoring that the current treatment with warfarin requires.
The story mentioned that apixabane would cost more than warafarin, and included a quote from a company spokesperson to indicate that the exact price is uncertain as the medication has not yet been approved. The story also presented a reasoned examination of total costs for the use of warafin that accounted not just for per pill costs but also the expenses associated with the routine blood draws to examine warafarin levels.
The story provided the absolute decrease in the number of strokes or clots, major bleeding events and hemorrhagic stroke as compared to the people in the study taking warafarin.
The story provided good insight about possible problems associated with apixabane in patients with coronary artery disease who were simultaneously taking two blood thinners in addition to apixabane.
The story provided a clear explanation about the nature of the patients, the size of the study, and the fact that it was a randomized clinical trial.
The story did not engage in overt disease mongering.
The story quoted a study researcher, a company spokesperson, and a cardiologist who did not appear to have ties to the study reported on.
The story compared the outcome measure of apixabane to warafarin; in addition, it indicated that there is another medication in the same category that has been recently approved by the FDA.
The story was clear that apixabane, the medication reported on, was experimental.
The story was clear that there is already a similar type of drug that has recently been approved for use by the FDA.
While the story referenced a news release, it does not appear to be its sole source of information.